A fibroblast activation protein degrader enhances cisplatin sensitivity in non‑small cell lung cancer
{{output}}
The therapeutic effect of cisplatin against non‑small cell lung cancer (NSCLC), the most common lung cancer, is limited by resistance. In the present study, a fibroblast activation protein (FAP) degrader (Pomalidomide‑PEG2‑FAP2286: FAP‑D) was utilized to e... ...
